Chinook Therapeutics, Inc. (Nasdaq: KDNY), today announced that Tom Frohlich, chief business officer, has been promoted to chief operating officer (COO) of Chinook and Andrew King, D.V.M, Ph.D., head of renal discovery and translational medicine, has been promoted to chief scientific officer (CSO) of Chinook
June 9, 2021
· 3 min read